ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2020
[Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia].
S Yang, Y Z Qin, Y Y Lai, H X Shi, Y Hou, X J Huang, Q Jiang
Open access · greenAbstract read
In one paragraphArticle in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors at 2 institutions in 1 country.
S YangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
Y Z QinPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
Y Y LaiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
H X ShiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
Y HouPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
X J HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
Q JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
Peking University People's Hospital · CNPeking University · CN
Funding
National Natural Science Foundation of China 81770161, 81970140
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myelogenous, Chronic, BCR-ABL PositivePleural EffusionAntineoplastic AgentsChildDasatinibHumansLymphoma, FollicularProtein Kinase InhibitorsRetrospective StudiesAntineoplastic AgentsDasatinibProtein Kinase InhibitorsDasatinibLeukemia, myelogenous, chronic, BCR-ABL positivePleural effusionPulmonary artery hypertension
Identifiers
PMID33445849
PMCPMC7840556
OpenAlexW3123960236
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390